Literature DB >> 16327977

Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.

Mitsutoshi Uchibori1, Yoshihiro Nishida, Tetsuro Nagasaka, Yoshihisa Yamada, Keisuke Nakanishi, Naoki Ishiguro.   

Abstract

Numerous studies have demonstrated a correlation of matrix metalloproteinase (MMP) overexpression with the prognosis of various kinds of cancer. The current study investigated whether the expression of MMPs is correlated with the prognosis of osteosarcoma. Expression levels of MMP-2, -9, MT1-MMP and TIMP-2 were examined immunohistochemically in samples from 47 patients with osteosarcoma. Correlation of the positivity of staining with prognosis was analyzed with the Kaplan-Meier method, and statistically analyzed with log-rank test. Co-localization of MMP-2, MT1-MMP and TIMP-2 was determined by double staining with fluorescence-conjugated antibodies. Activities of gelatinases in representative tissues were examined with gelatin zymography. MMP-2 was expressed strongly in 60% of cases (28/47), and MMP-9, MT1- MMP and TIMP-2 was strongly positive in 61% (29/47), 45% (21/47), and 91% (43/47), respectively. Increased MT1-MMP expression was associated significantly with poor prognosis in overall survival (P=0.0480). In cases of overexpression for both MMP-2 and MT1-MMP, there was a tendency for poor prognosis (P=0.0969). In 36 cases who underwent neoadjuvant chemotherapy, wide resection of the tumors and post-operative adjuvant chemotherapy, increased expression of MT1-MMP resulted in a significant negative prognostic factor for disease-free survival (P=0.0143). Also, co-overexpression of MT1-MMP and MMP-2 showed a tendency to correlate to the reduced disease-free survival (P=0.0502). Increased gelatinase activity was observed in tissues of co-overexpression of MT1-MMP and MMP-2. The results of this study demonstrate the correlation of MT1-MMP expression and the oncological outcome of osteosarcoma patients, suggesting the prognostic significance of these proteins in osteosarcoma patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16327977

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  37 in total

1.  Questions about XY Wen et al. entitled "Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis".

Authors:  Fanxiao Liu; Qingyu Zhang
Journal:  Tumour Biol       Date:  2015-02-08

2.  Characterization of human multicentric osteosarcoma using newly established cells derived from multicentric osteosarcoma.

Authors:  Y Yamamoto; N Yamamoto; K Tajima; A Ohno; Y Washimi; D Ishimura; O Washimi; H Yamada
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-04       Impact factor: 4.553

3.  Letter regarding Wen X.Y. et al. entitled "Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis".

Authors:  Hong-bin Guo; Tao Xiao
Journal:  Tumour Biol       Date:  2014-01-22

4.  Biomarkers in Osteosarcoma.

Authors:  Colin Kong; Marc F Hansen
Journal:  Expert Opin Med Diagn       Date:  2009-01-01

5.  EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma.

Authors:  Naohisa Futamura; Yoshihiro Nishida; Hiroshi Urakawa; Eiji Kozawa; Kunihiro Ikuta; Shunsuke Hamada; Naoki Ishiguro
Journal:  Tumour Biol       Date:  2014-01-31

Review 6.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

Review 7.  Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development.

Authors:  Lidiya S Orlichenko; Derek C Radisky
Journal:  Clin Exp Metastasis       Date:  2008-02-20       Impact factor: 5.150

8.  Sarcoma Tumor Microenvironment.

Authors:  Panagiotis Tsagozis; Jordi Gonzalez-Molina; Anna-Maria Georgoudaki; Kaisa Lehti; Joseph Carlson; Andreas Lundqvist; Felix Haglund; Monika Ehnman
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  MMP-14 can serve as a prognostic marker in patients with supraglottic cancer.

Authors:  Huiyan Zhang; Ming Liu; Yanan Sun; Jianguang Lu
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-03-13       Impact factor: 2.503

Review 10.  A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma.

Authors:  Hui Li; Kun Zhang; Li-hong Liu; Yurong Ouyang; Jie Bu; Hong-bin Guo; Tao Xiao
Journal:  Tumour Biol       Date:  2014-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.